A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR

著录项

• 来源
  《International Journal of Radiation Oncology, Biology, Physics》 |2018年第5期|共1页
• 作者

  Siu L.; Even C.; Mesia R.; Daste A.; Krauss J.; Saba N. F.; Nabell L.; Ready N. E.; Brana Garcia I.; Kotecki N.; Zandberg D. P.; Gilbert J.; Mehanna H.; Jarkowski A.; Melillo G.; Armstrong J. M.; Fayette J.;

  展开▼
• 作者单位

  Princess Margaret Canc Ctr Toronto ON Canada;

  Inst Gustave Roussy Villejuif France;

  Univ Barcelona Catalan Inst Oncol Dept Med Oncol Barcelona Spain;

  Hop St Andre Dept Oncol Med Bordeaux France;

  Natl Ctr Tumor Dis NCT Dept Med Oncol Heidelberg Germany;

  Emory Univ Winship Canc Inst Dept Hematol &

  Med Oncol Atlanta GA 30322 USA;

  Univ Alabama Birmingham Ctr Comprehens Canc Clin Studies Unit Birmingham AL 35294 USA;

  Duke Univ Med Ctr Durham NC USA;

  Hosp Univ Vall dHebron Barcelona Spain;

  Ctr Oscar Lambret Ctr Reg Lutte Canc Lille France;

  Univ Maryland Marlene &

  Stewart Greenebaum Comprehens Canc Ctr Baltimore MD 21201 USA;

  Henry Joyce Canc Clin Dept Hematol &

  Oncol Nashville TN USA;

  Univ Birmingham Inst Head &

  Neck Studies &

  Educ InHANSE Birmingham W Midlands England;

  AstraZeneca Gaithersburg MD USA;

  AstraZeneca Gaithersburg MD USA;

  AstraZeneca Gaithersburg MD USA;

  Univ Lyon Ctr Leon Berard Ctr Canc Clin Oncol Lyon France;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 放射医学;
• 关键词